References
1. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for
the treatment of metastatic renal cell carcinoma : a retrospective analysis
of response and survival in patients treated in the surgery branch at
the National Cancer Institute between 1986 and 2006. Cancer.
2008;113(2):293-301.
2. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380
(12):1116-1127.
3. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab
versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J
Med. 2018;378(14):1277-1290.
4. Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an Engineered
Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure,
and Marked Efficacy in Mouse Tumor Models. Clin Cancer Res.
2016;22(3):680-690.
5. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC.
Results of treatment of 255 patients with metastatic renal cell carcinoma
who received high-dose recombinant interleukin-2 therapy. Journal
of clinical oncology : official journal of the American Society of
Clinical Oncology. 1995;13(3):688-696.
6. Bentebibel SE, Hurwitz ME, Bernatchez C, et al. A First-in-Human
Study and Biomarker Analysis of NKTR-214, a Novel IL2Rbetagamma-
Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Cancer Discov. 2019;9(6):711-721.
7. A Dose Escalation and Cohort Expansion Study of NKTR-214 in
Combination With Nivolumab and Other Anti-Cancer Therapies in Patients
With Select Advanced Solid Tumors ( PIVOT-02)https://clinicaltrials.
gov/ct2/show/NCT02983045
18 Kidney Cancer Journal
8. Diab A, Hurwitz M, Cho D, et al. NKTR-214 (CD122-biased agonist)
plus nivolumab in patients with advanced solid tumors: Preliminary
phase 1/2 results of PIVOT. J Clin Oncol. 2018;36(15 suppl):3006.
9. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib
as initial therapy for metastatic renal cell carcinoma of intermediate or
poor risk (Alliance A031203 CABOSUN randomised trial): Progressionfree
survival by independent review and overall survival update. Eur J
Cancer. 2018;94:115-125.
10. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon
alfa-2a for treatment of metastatic renal cell carcinoma: a randomised,
double-blind phase III trial. Lancet. 2007;370(9605): 2103-
2111.
11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of
axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a
randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
12. Hurwitz M, Cho D, Balar A, et al. Baseline Tumor Immune Signatures
Associated with Response to Bempegaldesleukin (NKTR-214) and
Nivolumab. J Clin Oncol. 2019;37(7 suppl):2623.
13. Diab A, Puzanov I, Maio M, et al. Clinical Activity of BEMPEG Plus
NIVO in Previously Untreated Patients With Metastatic Melanoma: Updated
Results From the Phase 1/2 PIVOT-02 Study. J Immunother Cancer.
2019;7(suppl 1):O35.
14. Siefker-Radtke A, Fishman M, Balar AV, et al. Bempegaldesleukin*
(NKTR-214) + nivolumab in first-line advanced/metastatic urothelial
carcinoma: Updated results from PIVOT-02. J Clin Oncol. 2019;37(7
suppl):388. KCJ